IFNB1 and myeloid sarcoma: EAE has served as an experimental tool for the development of MS therapeutics, such as glatiramer acetate, mitoxantrone, and natalizumab (337, 338), and has been used to investigate the efficacy and safety of many other treatments, including methylprednisolone (339) for MS relapses and IFN-β, which cause disease exacerbation after treatment discontinuation (340).